The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy.

作者: Maciej Tarnowski , Agnieszka Paradowska-Gorycka , Ewa Dąbrowska-Zamojcin , Michal Czerewaty , Sylwia Słuczanowska-Głąbowska

DOI: 10.1517/17425255.2016.1121233

关键词:

摘要: Introduction: Rheumatoid arthritis (RA) is a systemic disease leading to joint destruction. The therapy of RA mainly based on disease-modifying anti-rheumatic drugs (DMARDs) and biological drugs. response treatment different among patients. Therefore, we have searched for factors that may predict the efficacy toxicity during in individual patients.Areas covered: This review presents role genetic polymorphisms as predictors patients with DMARDs (methotrexate, leflunomide, sulfasalazine) (anti-TNF-alpha antagonists, Tocilizumab, Rituximab).Expert opinion: Despite studies having shown an association between patients, majority these findings are still inconclusive inconsistent. We far from applying pharmacogenetic tests routine clinical practice can outcome treatment. Several factors, such small sample size...

参考文章(135)
Aurea Lima, Miguel Bernardes, Rita Azevedo, Joaquim Monteiro, Hugo Sousa, Rui Medeiros, Vítor Seabra, SLC19A1, SLC46A1 and SLCO1B1 Polymorphisms as Predictors of Methotrexate-Related Toxicity in Portuguese Rheumatoid Arthritis Patients Toxicological Sciences. ,vol. 142, pp. 196- 209 ,(2014) , 10.1093/TOXSCI/KFU162
Claire Immediato Daïen, Sylvie Fabre, Cécile Rittore, Stephan Soler, Vincent Daïen, Gautier Tejedor, Doris Cadart, Nicolas Molinari, Jean-Pierre Daurès, Christian Jorgensen, Isabelle Touitou, TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis Joint Bone Spine. ,vol. 79, pp. 471- 475 ,(2012) , 10.1016/J.JBSPIN.2011.10.007
JE Fonseca, T Carvalho, M Cruz, P Nero, M Sobral, AF Mourao, J Cavaleiro, D Ligeiro, I Abreu, M Carmo-Fonseca, JC Branco, Polymorphism at position –308 of the tumour necrosis factor α gene and rheumatoid arthritis pharmacogenetics Annals of the Rheumatic Diseases. ,vol. 64, pp. 793- 794 ,(2005) , 10.1136/ARD.2004.028167
George J. Weiner, Rituximab: Mechanism of Action Seminars in Hematology. ,vol. 47, pp. 115- 123 ,(2010) , 10.1053/J.SEMINHEMATOL.2010.01.011
Changsoo Paul Kang, Kyung-Wha Lee, Dae-Hyun Yoo, Changwon Kang, Sang-Cheol Bae, None, The influence of a polymorphism at position −857 of the tumour necrosis factor α gene on clinical response to etanercept therapy in rheumatoid arthritis Rheumatology. ,vol. 44, pp. 547- 552 ,(2005) , 10.1093/RHEUMATOLOGY/KEH550
J D Canete, B Suarez, M V Hernandez, R Sanmarti, I Rego, R Celis, C Moll, J A Pinto, F J Blanco, F Lozano, Influence of variants of Fcγreceptors IIA and IIIA on the ACR and EULAR responses to anti-TNFα therapy in rheumatoid arthritis Annals of the Rheumatic Diseases. ,vol. 68, pp. 1547- 1552 ,(2009) , 10.1136/ARD.2008.096982
Catherine Potter, Heather J Cordell, Anne Barton, Ann K Daly, Kimme L Hyrich, Derek A Mann, Ann W Morgan, Anthony G Wilson, John D Isaacs, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS, None, Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFκB signalling pathways Annals of the Rheumatic Diseases. ,vol. 69, pp. 1315- 1320 ,(2010) , 10.1136/ARD.2009.117309
Sandra Garcês, Jocelyne Demengeot, Elizabeth Benito-Garcia, The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis Annals of the Rheumatic Diseases. ,vol. 72, pp. 1947- 1955 ,(2013) , 10.1136/ANNRHEUMDIS-2012-202220